Aravive Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

CEO

Aravive heeft geen CEO, of we hebben geen gegevens over hen.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/01/29 07:33
Aandelenkoers aan het einde van de dag	2024/01/29 00:00
Inkomsten	2023/09/30
Jaarlijkse inkomsten	2022/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Aravive, Inc. wordt gevolgd door 16 analisten. van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
null null	BTIG
John Newman	Canaccord Genuity
Louise Chen	Cantor Fitzgerald & Co.

Aravive Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc., Annual General Meeting, Oct 02, 2023

High number of new directors

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Recent updates

Aravive Files Form 15

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc. Notifies Nasdaq of its Intention to File a Form 25 on or About January 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Aravive, Inc., Annual General Meeting, Oct 02, 2023

Consensus revenue estimates decrease by 51%

Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Consensus revenue estimates increase by 95%

Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 35%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive, Inc. Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian

Aravive Inc. Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 44%

Price target decreased to US$9.80

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aravive, Inc. announced that it has received $41.559988 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC, and other investors

Consensus forecasts updated

Aravive, Inc. announced that it expects to receive $41.55547 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC

Consensus forecasts updated

Aravive Receives Third Development Milestone from 3D Medicines

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Consensus revenue estimates increase by 10%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Aravive Q2 GAAP EPS misses, revenue beats

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive appoints Robert Geller as CMO

Price target decreased to US$18.20

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Aravive, Inc. Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 25%

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

High number of new directors

Consensus forecasts updated

Price target decreased to US$19.75

Aravive, Inc. Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Aravive, Inc. Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

High number of new directors

Aravive, Inc. announced that it has received $10.000001 million in funding from Eshelman Ventures, LLC

Aravive, Inc. announced that it expects to receive $10.000001 million in funding from Eshelman Ventures, LLC

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive Inc Announces First Patient Dosed in Phase 1B/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Consensus revenue estimates increase to US$7.34m

Aravive, Inc.(NasdaqGS:ARAV) dropped from Russell Microcap Growth Index

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Consensus revenue estimates increase to US$4.10m

Aravive, Inc. Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive EPS beats by $0.01, misses on revenue

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Insider exercised options to buy US$318k worth of stock.

Consensus revenue estimates increase to US$3.11m

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Full year 2020 earnings released: US$1.93 loss per share (vs US$1.57 loss in FY 2019)

Aravive, Inc. Announces Updated Data from Its Phase 1B Trial Evaluating Avb-500 in Platinum Resistant Ovarian Cancer

Aravive, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

New 90-day high: US$6.85

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Dr. Ray Tabibiazar Announces to Step Down from the Aravive Board of Directors